TY - JOUR AU - Fain, K. M. AU - Nachman, K. E. AU - Rutkow, L. PY - 2014 DA - 2014// TI - An Analysis of FDA’s Drug Safety Authorities: Challenges and Opportunities Under a New Regulatory Framework JO - N.Y.U. J. Legis. & Pub. Pol’y VL - 17 ID - Fain2014 ER - TY - STD TI - Prakash S, Valentine V. Timeline: The Rise and Fall of Vioxx. 2004. http://www.npr.org/templates/story/story.php?storyId=5470430. Accessed 13 Dec 2015 UR - http://www.npr.org/templates/story/story.php?storyId=5470430 ID - ref2 ER - TY - BOOK AU - Rubin, R. PY - 2004 DA - 2004// TI - How Did the Vioxx Debacle Happen? ID - Rubin2004 ER - TY - BOOK AU - Herper, M. PY - 2005 DA - 2005// TI - David Graham on the Vioxx Verdict ID - Herper2005 ER - TY - STD TI - 21 U.S. Code § 355-1 – Risk Evaluation and Mitigation Strategies. https://www.law.cornell.edu/uscode/text/21/355-1#. Accessed 13 Dec 2015. UR - https://www.law.cornell.edu/uscode/text/21/355-1 ID - ref5 ER - TY - STD TI - A Brief Overview of Risk Evaluation and Mitigation Strategies (REMS). 2015. http://www.fda.gov/downloads/AboutFDA/Transparency/Basics/UCM328784.pdf. Accessed 13 Dec 2015. UR - http://www.fda.gov/downloads/AboutFDA/Transparency/Basics/UCM328784.pdf ID - ref6 ER - TY - JOUR AU - Tucker, D. AU - Wells, G. F. PY - 2014 DA - 2014// TI - Emerging Competition Issues Involving Follow-on Biologics JO - Antitrust VL - 29 ID - Tucker2014 ER - TY - JOUR AU - Neyarapally, G. A. PY - 2011 DA - 2011// TI - A Review of Recent Federal Legislative and Policy Initiatives to Enhance the Development and Evaluation of High Value Drugs in the United States JO - DePaul J. Health Care L. VL - 14 ID - Neyarapally2011 ER - TY - STD TI - Optimal Futures for Risk Evaluation and Mitigation Strategies (REMS). 2010. http://www.altfutures.org/pubs/pharma/IAF%20Optimal%20Futures%20for%20Risk%20Evaluation%20&%20Mitigations%20Strategies%20%28REMS%29%20Workshop%20Report.pdf. Accessed 13 Dec 2015. UR - http://www.altfutures.org/pubs/pharma/IAF%20Optimal%20Futures%20for%20Risk%20Evaluation%20&%20Mitigations%20Strategies%20%28REMS%29%20Workshop%20Report.pdf ID - ref9 ER - TY - STD TI - United States of America Congressional Record 153 Cong. Rec. S11937-01. 2007. https://www.congress.gov/crec/2007/09/21/CREC-2007-09-21.pdf. Accessed 13 Dec 2015. UR - https://www.congress.gov/crec/2007/09/21/CREC-2007-09-21.pdf ID - ref10 ER - TY - JOUR AU - Faden, L. B. AU - Milne, C. P. PY - 2008 DA - 2008// TI - Pharmacovigilance Activities in the United States, European Union and Japan: Harmonic Convergence or Convergent Evolution? JO - Food & Drug L.J VL - 63 ID - Faden2008 ER - TY - STD TI - Background Materials for REMS Standardization and Evaluation Public Meeting. 2013. http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm358784.htm#2.2. Accessed 13 Dec 2015. UR - http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm358784.htm#2.2 ID - ref12 ER - TY - STD TI - 21 U.S. Code § 352 – Misbranded Drugs and Devices. https://www.law.cornell.edu/uscode/text/21/352. Accessed 13 Dec 2015. UR - https://www.law.cornell.edu/uscode/text/21/352 ID - ref13 ER - TY - STD TI - 21 U.S. Code § 355 – New Drugs. https://www.law.cornell.edu/uscode/text/21/355. Accessed 13 Dec 2015. UR - https://www.law.cornell.edu/uscode/text/21/355 ID - ref14 ER - TY - STD TI - Standardizing and Evaluating Risk Evaluation and Mitigation Strategies (REMS). 2014. http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM415751.pdf. Accessed 13 Dec 2015. UR - http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM415751.pdf ID - ref15 ER - TY - STD TI - Released REMS. 2014. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm393231.htm Accessed 13 Dec 2015. UR - http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm393231.htm ID - ref16 ER - TY - STD TI - Approved Risk Evaluation and Mitigation Strategies (REMS). 2015. http://www.accessdata.fda.gov/scripts/cder/rems/index.cfm Accessed 13 Dec 2015. UR - http://www.accessdata.fda.gov/scripts/cder/rems/index.cfm ID - ref17 ER - TY - STD TI - Guidance for Industry: Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications. 2009. http://www.fda.gov/downloads/Drugs/Guidances/UCM184128.pdf. Accessed 13 Dec 2015. UR - http://www.fda.gov/downloads/Drugs/Guidances/UCM184128.pdf ID - ref18 ER - TY - JOUR AU - Megaw, C. PY - 2014 DA - 2014// TI - Reviving Essential Facilities to Prevent REMS Abuses JO - Colum. J.L. & Soc. Probs. VL - 47 ID - Megaw2014 ER - TY - STD TI - Doyle K, Jauregui J, Tyson G. REMS: The New Reality. http://www.campbellalliance.com/articles/campbell_alliance_REMS_article.pdf. Accessed 13 Dec 2015. UR - http://www.campbellalliance.com/articles/campbell_alliance_REMS_article.pdf ID - ref20 ER - TY - STD TI - E.g., Proposed Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS). 2011. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM261983.pdf. Accessed 13 Dec 2015. UR - http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM261983.pdf ID - ref21 ER - TY - STD TI - Draft Guidance: How to Obtain a Letter from FDA Stating that Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable REMS for RLD. 2014. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM425662.pdf. Accessed 13 Dec 2015 UR - http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM425662.pdf ID - ref22 ER - TY - STD TI - Abbreviated New Drug Application (ANDA): Generics. 2015. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/. Accessed 13 Dec 2015. UR - http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ ID - ref23 ER - TY - JOUR AU - Upadhye, S. AU - Lang, B. PY - 2014 DA - 2014// TI - The FDA and Patent, Antitrust, and Property Takings Laws: Strange Bedfellows Useful to Unblocking Access to Blocked Drugs JO - B.U. J. Sci. & Tech. L. VL - 20 ID - Upadhye2014 ER - TY - BOOK AU - Carrier, M. AU - Kesselheim, A. PY - 2015 DA - 2015// TI - The Daraprim Price Hike and a Role for Antitrust ID - Carrier2015 ER - TY - JOUR AU - Tucker, D. AU - Wells, G. F. AU - Sheer, M. E. PY - 2014 DA - 2014// TI - REMS: The Next Pharmaceutical Enforcement Priority? JO - Antitrust VL - 28 ID - Tucker2014 ER - TY - BOOK AU - Brill, A. PY - 2014 DA - 2014// TI - Lost Prescription Drug Savings from Use of REMS Programs to Delay Generic Market Entry ID - Brill2014 ER - TY - STD TI - Sabril. http://www.drugs.com/monograph/sabril.html. Accessed 13 Dec 2015. UR - http://www.drugs.com/monograph/sabril.html ID - ref28 ER - TY - STD TI - NDA 22-081 Letairis (ambrisentan): Risk Evaluation and Mitigation Strategy (REMS). 2014. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM164969.pdf. Accessed 13 Dec 2015. UR - http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM164969.pdf ID - ref29 ER - TY - STD TI - Federal Register: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products. 2013. Accessed 13 Dec 2015 ID - ref30 ER - TY - STD TI - Mutual Pharmaceuticals Co. v. Bartlett, 133 S. Ct. 2466 (2013). 2013. https://www.law.cornell.edu/supremecourt/text/12-142. Accessed 13 Dec 2015. UR - https://www.law.cornell.edu/supremecourt/text/12-142 ID - ref31 ER - TY - STD TI - Pliva v. Mensing, 131 S. Ct. 2567 (2011). 2011. http://www.supremecourt.gov/opinions/10pdf/09-993.pdf. Accessed 13 Dec 2015. UR - http://www.supremecourt.gov/opinions/10pdf/09-993.pdf ID - ref32 ER - TY - STD TI - Guidance: Medication Guides—Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS). 2011. http://www.fda.gov/downloads/Drugs/../Guidances/UCM244570.pdf. Accessed 13 Dec 2015. UR - http://www.fda.gov/downloads/Guidances/UCM244570.pdf ID - ref33 ER - TY - BOOK AU - Maness, R. AU - Segers, B. PY - 2014 DA - 2014// TI - Refusal to Deal Under FDA Imposed Risk Evaluation and Mitigation Strategies (REMS): Economic Considerations ID - Maness2014 ER - TY - STD TI - FDA Drug Safety Communication: Modified Risk Evaluation and Mitigation Strategies (REMS) for Nplate (romiplostim) and Promacta (eltrombopag). 2011. http://www.fda.gov/Drugs/DrugSafety/ucm280165.htm. Accessed 13 Dec 2015 UR - http://www.fda.gov/Drugs/DrugSafety/ucm280165.htm ID - ref35 ER - TY - STD TI - Full FDA Prescription Drug List. http://www.medilexicon.com/drugsearch.php?z=true. Accessed 13 Dec 2015. UR - http://www.medilexicon.com/drugsearch.php?z=true ID - ref36 ER - TY - BOOK PY - 2011 DA - 2011// TI - New Molecular Entity (NME) & New BLA Calendar Year Approvals as of December 31, 2010 ID - ref37 ER - TY - STD TI - 2011 Novel New Drugs Summary. 2012. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM293663.pdf. Accessed 13 Dec 2015. UR - http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM293663.pdf ID - ref38 ER - TY - STD TI - 2012 Novel New Drugs Summary. 2013. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM337830.pdf. Accessed 13 Dec 2015. UR - http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM337830.pdf ID - ref39 ER - TY - STD TI - Novel New Drugs 2013 Summary. 2014. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM381803.pdf. Accessed 13 Dec 2015 UR - http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM381803.pdf ID - ref40 ER - TY - STD TI - Novel New Drugs 2014 Summary. 2015. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM430299.pdf. Accessed 13 Dec 2015 UR - http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM430299.pdf ID - ref41 ER - TY - STD TI - FDA Approved Drug Products. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Search_Drug_Name. Accessed 13 Dec 2015. UR - http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Search_Drug_Name ID - ref42 ER - TY - STD TI - Prometheus Laboratories Inc. Citizen Petition. 2013. http://www.fdalawyersblog.com/Prometheus_Laboratories_Inc_Citizen_Petition.pdf. Accessed 13 Dec 2015. UR - http://www.fdalawyersblog.com/Prometheus_Laboratories_Inc_Citizen_Petition.pdf ID - ref43 ER - TY - STD TI - Currently Approved Shared System REMS. http://www.accessdata.fda.gov/scripts/cder/rems/index.cfm. Accessed 13 Dec 2015. UR - http://www.accessdata.fda.gov/scripts/cder/rems/index.cfm ID - ref44 ER - TY - STD TI - Guidance for Industry: ANDA Submissions—Refuse-to-Receive Standards. 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm370352.pdf. Accessed 13 Dec 2015. UR - http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm370352.pdf ID - ref45 ER - TY - STD TI - Fair Access for Safe and Timely Generics Act of 2014, H.R. 5657. 2014. https://www.gpo.gov/fdsys/pkg/BILLS-113hr5657ih/pdf/BILLS-113hr5657ih.pdf. Accessed 13 Dec 2015. UR - https://www.gpo.gov/fdsys/pkg/BILLS-113hr5657ih/pdf/BILLS-113hr5657ih.pdf ID - ref46 ER - TY - STD TI - E.g., Caribbean Broad. Sys., Ltd. v. Cable & Wireless PLC, 148 F.3d 1080, 1088 (D.C. Cir. 1998). 1998. http://openjurist.org/148/f3d/1080/caribbean-broadcasting-system-ltd-v-cable-and-wireless-plc. Accessed 13 Dec 2015. UR - http://openjurist.org/148/f3d/1080/caribbean-broadcasting-system-ltd-v-cable-and-wireless-plc ID - ref47 ER - TY - STD TI - FAST Generics Act Would Amend the FDC Act to Address REMS/Restritected Access Programs and Biostudy Sample Availability. FDA Law Blog. 2014. http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2014/09/fast-generics-act-would-amend-the-fdc-act-to-address-remsrestricted-access-programs-and-biostudysam.html. Accessed 18 Jan 2016. UR - http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2014/09/fast-generics-act-would-amend-the-fdc-act-to-address-remsrestricted-access-programs-and-biostudysam.html ID - ref48 ER - TY - STD TI - Dr. Reddy’s Laboratories, Inc. Citizen Petition. 2009. http://www.fdalawyersblog.com/Dr_Reddy%27s_Laboratories,_Inc_-_Citizen_Petition.pdf. Accessed 13 Dec 2015. UR - http://www.fdalawyersblog.com/Dr_Reddy%27s_Laboratories,_Inc_-_Citizen_Petition.pdf ID - ref49 ER - TY - STD TI - FDA CDER to Dr Reddys Laboratories Inc Partial Petition Approval and Denial. 2013. http://www.regulations.gov/#!documentDetail;D=FDA-2009-P-0266-0006. Accessed 13 Dec 2015. UR - http://www.regulations.gov/#!documentDetail;D=FDA-2009-P-0266-0006 ID - ref50 ER - TY - BOOK AU - Reichertz, P. AU - Ross, C. PY - 2015 DA - 2015// TI - New FDA Draft Guidance on REMS and Bioequivalence Studies: Does New Procedure Secure ANDA Applicants the Right to Obtain Samples? ID - Reichertz2015 ER - TY - STD TI - Conte v. Wyeth, 85 Cal. Rptr. 3d 299 (Cal. Ct. App. 2008). 2008. https://casetext.com/case/conte-v-wyeth-inc. Accessed 13 Dec 2015. UR - https://casetext.com/case/conte-v-wyeth-inc ID - ref52 ER -